These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 4804083)

  • 1. Control of hormonal treatment of carcinoma of the prostate.
    Frick J
    Urol Res; 1973 Oct; 1(3):120-1. PubMed ID: 4804083
    [No Abstract]   [Full Text] [Related]  

  • 2. Physiologic basis for hormonal theapy in carcinoma of the prostate.
    Walsh PC
    Urol Clin North Am; 1975 Feb; 2(1):125-40. PubMed ID: 48206
    [No Abstract]   [Full Text] [Related]  

  • 3. [Hormonal changes in carcinoma of the prostate].
    Rodrigues-Netto Júnior N; Da Silva RP; Hernández AJ
    Rev Paul Med; 1979; 94(1-2):24-6. PubMed ID: 120973
    [No Abstract]   [Full Text] [Related]  

  • 4. The hormonal effects of antiandrogen (SH-714) treatment in man.
    Schoonees R; Schalch DS; Murphy GP
    Invest Urol; 1971 May; 8(6):635-9. PubMed ID: 5578209
    [No Abstract]   [Full Text] [Related]  

  • 5. Hormone hanges in carcinoma of prostate.
    Straffon WG
    Br J Urol; 1970 Dec; 42(6):743. PubMed ID: 5491936
    [No Abstract]   [Full Text] [Related]  

  • 6. Principles of endocrine manipulation in the treatment of prostatic cancer.
    Neumann F
    Prog Clin Biol Res; 1985; 185A():73-98. PubMed ID: 3898136
    [No Abstract]   [Full Text] [Related]  

  • 7. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate.
    Varenhorst E; Wallentin L; Carlström K
    Scand J Urol Nephrol; 1982; 16(1):31-6. PubMed ID: 6211762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
    Guess B; Scholz M
    J Urol; 2001 May; 165(5):1644-5. PubMed ID: 11345950
    [No Abstract]   [Full Text] [Related]  

  • 9. Endocrine factors in the treatment of prostatic cancer.
    Pierrepoint CG; Turkes AO; Walker KJ; Harper ME; Wilson DW; Peeling WB; Griffiths K
    Prog Clin Biol Res; 1985; 185A():51-72. PubMed ID: 3162177
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.
    Smith JA; Glode LM; Wettlaufer JN; Stein BS; Glass AG; Max DT; Anbar D; Jagst CL; Murphy GP
    Urology; 1985 Feb; 25(2):106-14. PubMed ID: 3918369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma prolactin, GH, LH, FSH, TSH and testosterone during treatment of prostatic carcinoma with oestrogens.
    Boyns AR; Cole EN; Phillips ME; Hillier SG; Cameron EH; Griffiths K; Shahmanesh M; Feneley RC; Hartog M
    Eur J Cancer (1965); 1974 Jul; 10(7):445-9. PubMed ID: 4376085
    [No Abstract]   [Full Text] [Related]  

  • 12. [Testicular endocrine function appraised by the determination of testosterone and luteinizing hormone in the same blood test].
    Helgeland A; Norman N; Vogt JH; Aakvaag A
    Nord Med; 1970 Apr; 83(16):493-7. PubMed ID: 5426414
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of prostate cancer with gonadotropin-releasing hormone agonists.
    Labrie F; Dupont A; Bélanger A; St-Arnaud R; Giguère M; Lacourcière Y; Emond J; Monfette G
    Endocr Rev; 1986 Feb; 7(1):67-74. PubMed ID: 3514203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroid hormone concentrations in relation to patient prognosis and prostate tumour grade.
    Harper ME; Wilson DW; Jensen HM; Pierrepoint CG; Griffiths K
    J Steroid Biochem; 1987; 27(1-3):521-4. PubMed ID: 3121925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding capacity of testosterone-estradiol-binding globulin (TeBG), total and calculated unbound concentrations of testosterone in patients with carcinoma of the prostate treated with orchidectomy or estrogens.
    Damber JE; Bergman B; Södergård R; Tomić R
    J Endocrinol Invest; 1983 Apr; 6(2):91-4. PubMed ID: 6683289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced carcinoma of the prostate- does the pre-treatment Leydig cell function determine the response to orchidectomy?
    Houghton AL; Jacobs HS
    Postgrad Med J; 1978 Apr; 54(630):261-4. PubMed ID: 662791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of serum testosterone and LH determination in the hormonal therapy of prostatic cancer].
    Scheinar J; Hruska F; Talas M; Janousková M; Fingerová H
    Rozhl Chir; 1978 Dec; 57(12):805-12. PubMed ID: 734535
    [No Abstract]   [Full Text] [Related]  

  • 18. Bilateral adrenalectomy for advanced prostatic carcinoma.
    Schoonees R; Schalch DS; Reynoso G; Murphy GP
    J Urol; 1972 Jul; 108(1):123-5. PubMed ID: 5033992
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of orchidectomy performed after cessation of estrogen therapy on serum testosterone concentrations in patients with prostatic carcinoma.
    Tomić R; Damber JE
    Urol Int; 1987; 42(6):441-4. PubMed ID: 3129850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone changes in patients with prostatic carcinoma during treatment with estramustine phosphate.
    Fosså SD; Fosså J; Aakvaag A
    J Urol; 1977 Dec; 118(6):1013-8. PubMed ID: 926240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.